Celltrion starts Phase I and Phase III clinical trials for Humira biosimilar

Celltrion recently announced that they made a clinical trial application for ‘CT-P17,’ a biosimilar referencing the rheumatoid arthritis therapy ‘Humira(generic name: adalimumab),’ to the U.K. Medicines and Healthcare Products Regulatory Agency(MHRA).

Celltrion said they would start a Phase I clinical trial to evaluate the product’s pharmacokinetics and safety in the U.K. while conducting a gl...